Alpha 2.0
Login Register
» Authors » Suparna B Wedam

Suparna B Wedam

Explore the profile of Suparna B Wedam including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 244
Followers 0
Related Specialties
Oncology
Radiology
Top 10 Co-Authors
Laleh Amiri-Kordestani
Julia A Beaver
Rajeshwari Sridhara
Erik Bloomquist
Richard Pazdur
Jennifer J Gao
Seth M Steinberg
Shenghui Tang
Amna Ibrahim
Sandra M Swain
Published In
J Clin Oncol
Lancet Oncol
Radiology
Affiliations
Soon will be listed here.
Recent Articles
1.
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Gao J, Cheng J, Prowell T, Bloomquist E, Tang S, Wedam S, et al.
Lancet Oncol . 2021 Oct; 22(11):1573-1581. PMID: 34656225
Background: Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are oral targeted agents approved for use in combination with endocrine therapy as first-line or second-line treatment of patients with hormone receptor-positive, HER2-negative, advanced...
2.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Gao J, Cheng J, Bloomquist E, Sanchez J, Wedam S, Singh H, et al.
Lancet Oncol . 2019 Dec; 21(2):250-260. PMID: 31859246
Background: Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are indicated with endocrine therapy as first-line or second-line treatment for hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer. We aimed to investigate the...
3.
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer
Seidman A, Bordeleau L, Fehrenbacher L, Barlow W, Perlmutter J, Rubinstein L, et al.
J Clin Oncol . 2018 Sep; 36(32):3259-3268. PMID: 30212295
Purpose: To provide evidence-based consensus recommendations on choice of end points for clinical trials in metastatic breast cancer, with a focus on biologic subtype and line of therapy. Methods: The...
4.
US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments
Wedam S, Beaver J, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg K, et al.
J Clin Oncol . 2018 Mar; 36(12):1225-1231. PMID: 29522361
Purpose The outcome and proportion of patients with bone-only (BO) metastatic breast cancer (MBC) has not been well described. We sought to describe the differential outcomes of patients with BO...
5.
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience
Thukral A, Thomasson D, Chow C, Eulate R, Wedam S, Gupta S, et al.
Radiology . 2007 Aug; 244(3):727-35. PMID: 17709827
Purpose: To retrospectively compare three dynamic contrast material-enhanced magnetic resonance (MR) imaging (dynamic MR imaging) analytic methods to determine the parameter or combination of parameters most strongly associated with changes...
6.
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
Low J, Wedam S, Lee J, Berman A, Brufsky A, Yang S, et al.
J Clin Oncol . 2005 Apr; 23(12):2726-34. PMID: 15837987
Purpose: Ixabepilone (BMS-247550) is an epothilone B analog that stabilizes microtubules and has antitumor activity in taxane-refractory patients in phase I studies. In a phase II trial, we evaluated the...